AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PHOSLOCK ENVIRONMENTAL TECHN

0.008

0.000

Volume:789.75K

Turnover:6.27K

Market Cap:5.00M

PE:-0.50

High:0.008

Open:0.008

Low:0.007

Close:0.008

52wk High:0.025

52wk Low:0.006

Shares:624.39M

Float Shares:619.98M

Volume Ratio:0.63

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.018

ROE:-26.47%

ROA:-18.42%

PB:0.56

PE(LYR):-0.45

Loading ...

Overview Company News Filings

Ester Industries JV Acquires Land for Greenfield Infinite Loop Plant

MT Newswires Live

Telix Receives FDA Complete Response Letter for Biologics License Application for Investigational PET Agent, Shares Fall 19%

MT Newswires Live

Clarity Says Imaging Product Shows Superior Results in Phase 2 Trial Versus Standard of Care; Shares Jump 3%

MT Newswires Live

Malaysian Shares Rebound Midweek Tracking Gains of Regional Markets

MT Newswires Live

Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France

MT Newswires Live

Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma

MT Newswires Live

Phoslock Environmental Technologies to Recover Costs from Levitt Robinson Legal Proceedings

MT Newswires Live

Top Midday Decliners

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PET.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PET.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PET.AU\",,,,,undefined,":{"symbol":"PET.AU","market":"AU","secType":"STK","nameCN":"PHOSLOCK ENVIRONMENTAL TECHN","latestPrice":0.008,"timestamp":1760332320000,"preClose":0.008,"halted":0,"volume":789748,"delay":0,"nameEN":"PHOSLOCK ENVIRONMENTAL TECHN","floatShares":619978191,"shares":624390509,"eps":-0.015899,"marketStatus":"Not Yet Opened","change":0,"latestTime":"10-13 16:12:00 AEDT","open":0.008,"high":0.008,"low":0.007,"amount":6268,"amplitude":0.125,"askPrice":0.009,"askSize":2197634,"bidPrice":0.007,"bidSize":2049142,"shortable":3,"etf":0,"ttmEps":-0.015899,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1760396400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1760310000000,1760331600000]],"volumeRatio":0.633335,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PET.AU\",,,,,undefined,":{"symbol":"PET.AU","floatShares":619978191,"roa":"-18.42%","roe":"-26.47%","lyrEps":-0.017956,"volumeRatio":0.633335,"shares":624390509,"dividePrice":0,"high":0.008,"amplitude":0.125,"preClose":0.008,"low":0.007,"week52Low":0.006,"pbRate":"0.56","psRate":"3.11","week52High":0.025,"institutionHeld":0,"latestPrice":0.008,"committee":-0.034966,"eps":-0.015899,"divideRate":0,"volume":789748,"delay":0,"ttmEps":-0.015899,"open":0.008,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.007,"prevQuarterClose":0.007,"fiveDayClose":0.008,"twentyDayClose":0.008,"sixtyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PET.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-02-21","symbol":"PET.AU","reason":null,"defaultRemindTime":1708470000000,"announcedDate":"2023-12-15","type":"delisting","dateTimestamp":1708434000000},{"date":"2022-03-11","symbol":"PET.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1646953200000,"name":null,"time":"","dateTimestamp":1646917200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PET.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PET.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564339801","title":"Ester Industries JV Acquires Land for Greenfield Infinite Loop Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=2564339801","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564339801?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:46","pubTimestamp":1756899968,"startTime":"0","endTime":"0","summary":"Ester Industries  said its joint venture Ester Loop Infinite Technologies has signed an agreement with a group of sellers to acquire land near Surat, Gujarat, for a Greenfield Chemical Recycling PlantThe land will be acquired at a project cost of about 16 billion Indian rupees, according to a company filing on Wednesday.The facility will recycle polyester textile waste into virgin-quality polyethylene terephthalate  resin with an initial capacity of 70,000 metric tons per year and potential expansion of 100,000 metric tons, the company said in the filing.The plant will operate on roughly 80% renewable electricity and biofuel, aiming to reduce carbon emissions by up to 80% compared with conventional PET production, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","PET.AU"],"gpt_icon":0},{"id":"2562068727","title":"Telix Receives FDA Complete Response Letter for Biologics License Application for Investigational PET Agent, Shares Fall 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562068727","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562068727?lang=en_us&edition=fundamental","pubTime":"2025-08-28 11:21","pubTimestamp":1756351263,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received a complete response letter from the US Food and Drug Administration  for the biologics license application for TLX250-CDx, an investigational positron emission tomography  agent used to diagnose and characterize renal masses as clear cell renal cell carcinoma, according to a Thursday Australian bourse filing.The letter said that the regulator identified deficiencies relating to the chemistry, manufacturing, and controls package of the agent. The FDA documented notices of deficiency issued to two third-party manufacturing and supply chain partners.The regulator requested additional data to establish comparability between the drug product used in the ZIRCON phase three clinical trial and the scaled-up manufacturing process intended for commercial use.The firm said that the submission remediation will begin immediately, and it will request a Type A meeting with the FDA to address the highlighted deficiencies. It plans to continue to provide patient access t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","TLX.AU","BK7067","BK4192","PET.AU","PET"],"gpt_icon":0},{"id":"2541145960","title":"Clarity Says Imaging Product Shows Superior Results in Phase 2 Trial Versus Standard of Care; Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541145960","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541145960?lang=en_us&edition=fundamental","pubTime":"2025-06-05 11:05","pubTimestamp":1749092742,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said results from a phase 2 diagnostic imaging study in patients with known or suspected neuroendocrine tumors showed that lesion detection by copper-64-Sartate outpe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SMP","BK7096","PET.AU","XJO.AU","XKO.AU","PET","BK4192","BK7047","BK4124","CU6.AU","XAO.AU"],"gpt_icon":0},{"id":"2533603382","title":"Malaysian Shares Rebound Midweek Tracking Gains of Regional Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2533603382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533603382?lang=en_us&edition=fundamental","pubTime":"2025-05-07 17:44","pubTimestamp":1746611072,"startTime":"0","endTime":"0","summary":"Malaysian shares ended in the green on Wednesday, tracking regional gains. The investor interest rebounded amid easing trade tensions.The FTSE Bursa Malaysia KLCI, the main gauge of Malaysian stocks, gained 13.10 points, to end 0.85% higher at 1,549.90. The day range was between 1,536.56 and 1,549.90.Malaysia officially imposed definitive anti-dumping duties on imports of Polyethylene Terephthalate  from China-ranging between 2.29% and 11.74%, and from Indonesia at 37.44%, effective immediately. The Ministry of Investment, Trade and Industry  said the decision follows the conclusion of its months-long probe into alleged unfair trade practices.In corporate news, shares of Malaysian Genomics Resource Center  dropped 6% after its chief operating officer Muhammad Badri Bin Hussin resigned on Monday, May 5, citing personal commitment.Shares of Able Global  gained over 3% after Glass Lewis issued a controversy alert ahead of the company's May 27 annual meeting, citing serious ESG-related gov","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","PET.AU","MITI","BK4192","PET","BK7047"],"gpt_icon":0},{"id":"2531291299","title":"Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291299?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:49","pubTimestamp":1745884196,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received marketing authorization in France for Illuccix, its prostate cancer positron emission tomography  imaging agent, the company said in a statement Monday.Illucix is indicated in France for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer, the statement said.The company is partnering with IRE Group subsidiary IRE ELiT to market and promote Illuccix in France, according to the statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET","PET.AU","BK7067","TLX.AU","BK4192","BK7047","TLX"],"gpt_icon":0},{"id":"2524818124","title":"Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524818124","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524818124?lang=en_us&edition=fundamental","pubTime":"2025-04-02 13:19","pubTimestamp":1743571140,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma , according to a Tuesday statement by the company.The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography , the statement said.TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.The study will inform future therapeutic approaches for treating the disease, the company said.Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.Shares of the company fell 3% on market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","PET.AU","BK4192","BK7047","PET"],"gpt_icon":0},{"id":"2522597426","title":"Phoslock Environmental Technologies to Recover Costs from Levitt Robinson Legal Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522597426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522597426?lang=en_us&edition=fundamental","pubTime":"2025-03-28 13:30","pubTimestamp":1743139813,"startTime":"0","endTime":"0","summary":"Phoslock Environmental Technologies  is working closely with its legal advisors on ways to recover costs as the first prospective respondent in a legal proceeding filed by Levitt Robinson, according to a Friday filing with the Australian bourse.Earlier this month, the Federal Court dismissed the proceeding and ordered the prospective applicants to pay the costs of the prospective respondents, per the filing.A separate group proceeding filed by Banton Group remains ongoing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","PET.AU"],"gpt_icon":0},{"id":"2522752706","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522752706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522752706?lang=en_us&edition=fundamental","pubTime":"2025-03-25 02:37","pubTimestamp":1742841460,"startTime":"0","endTime":"0","summary":"23andMe  filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive, less than a month after she attempted to acquire the genetic testing firm.Shares slumped 57%, with intraday trading volume of over 5.5 million against a daily average of about 292,000.TransCode Therapeutics  said Sunday it agreed to sell 10.25 million shares and warrants to buy up to 10.25 million shares at $0.98 per share and warrant to raise some $10 million.Shares sank 38% as intraday trading volume rose to over 15.5 million from a daily average of about 6.36 million.Wag!Group  said Monday its board is advancing a review of \"strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the company or its assets.\"Shares slid 22% as intraday trading volume rose to over 1.3 million from a daily average of about 665,0","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ME","PET","BK4121","PET.AU","MEHCQ","BK4192","BK7047","RNAZ","BK4539","BK4196"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}